MaxCyte (MXCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, to elect three Class II directors and ratify the selection of CohnReznick LLP as independent auditor for fiscal year 2026.
Record date for voting is April 21, 2026, with 107,121,672 shares outstanding and entitled to vote.
Proxy materials are available online, and shareholders are encouraged to vote via internet, phone, or mail.
Voting matters and shareholder proposals
Shareholders will vote on the election of Patrick Balthrop, Cynthia Collins, and Stanley Erck as Class II directors for terms expiring in 2029.
Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Shareholder proposals for the 2027 meeting must be submitted by December 30, 2026, with director nominations due between February 17 and March 19, 2027.
Board of directors and corporate governance
Board consists of nine members divided into three classes, with a majority deemed independent under Nasdaq standards.
Board leadership is separated, with an independent chairman and CEO roles held by different individuals.
Board diversity matrix shows two female and seven male directors, with representation from Asian, Middle Eastern, and White backgrounds.
Board and committees met regularly, with all members attending at least 75% of meetings.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Code of Conduct and Ethics, insider trading policies, and corporate governance guidelines are in place.
Latest events from MaxCyte
- Scalable cell engineering platform drives recurring revenue and supports a robust clinical pipeline.MXCT
Corporate presentation - Q2 2026 revenue fell 15%, but net loss narrowed and guidance and cash outlook were reaffirmed.MXCT
Q2 2026 - Q1 2026 revenue fell 7%, net loss narrowed, and a $10M share repurchase was authorized.MXCT
Q1 2026 - Restructuring, SecureDx integration, and new launches set the stage for global growth in 2026.MXCT
Stephens Annual Investment Conference - Electroporation and SPL growth drive strong momentum in cell and gene therapy markets.MXCT
Stifel 2024 Healthcare Conference - Q3 revenue rose 2% to $8.2M, core revenue up 23%, and six new SPLs set a record.MXCT
Q3 2024 - Q2 2024 revenue up 15% to $10.4M, SPL revenue surged 279%, and cash guidance raised to $180M.MXCT
Q2 2024 - Q1 2025 revenue fell 8% to $10.4M, but core business grew and guidance is reaffirmed.MXCT
Q1 2025 - 2025 guidance targets 8–15% core revenue growth and $5M SPL revenue, leveraging SeQure Dx.MXCT
Q4 2024